Share This

Related Topics News -

     
 Detail   |   Print    Next page > 
     
創勝集團-B夥安捷倫科技進行胃癌治療臨床試驗
2024-04-09T  
《公司業績》創勝集團-B全年虧損擴至4.63億人幣
2024-03-28T  
創勝集團-B公布胃癌藥物更新療效數據
2023-10-24T  
創勝集團-B治療胃癌藥物獲美國批准開展全球III期關鍵性試驗
2023-10-04T  
《公司業績》創勝集團中期虧損擴至2.38億人民幣
2023-08-23T  
創勝集團-B治療骨密度降低藥物獲內地批准開展臨床試驗
2023-07-31T  
創勝集團(06628.HK)治療癌症藥物獲中韓批准開展III期臨床試驗
2023-07-07T  
創勝集團-B(06628.HK)於ESMO世界胃腸道腫瘤大會公布OSEMITAMAB聯合CAPOX療效數據
2023-06-30T  
創勝集團-B(06628.HK)治療胃癌藥物研究表明具抑制腫瘤生長作用
2023-06-06T  
創勝集團-B(06628.HK)治療中國骨密度降低患者藥物臨床數據顯示耐受性良好
2023-05-17T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.